Takara Bio strengthens its IP position on single cell RNA-seq
|
MOUNTAIN VIEW, Calif., July 18, 2018 /PRNewswire/ -- Takara Bio USA, Inc., (TBUSA, formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of Takara Bio Inc., is proud to announce that patent JP6336080B--covering the Smart-seq2 method, developed by Rickard Sandberg and exclusively licensed to TBUSA by the Ludwig Institute--has been awarded by the Japan Patent Office. Additional patents regarding the Smart-seq2 technology are pending in the U.S. and other regions. Because our scientists are dedicated to developing solutions for next-generation sequencing of challenging and low-input sample types, in 2015 TBUSA entered into an agreement with Ludwig Cancer Research to exclusively license the Smart-seq2 method. This advancement further bolstered our portfolio of NGS products, already powered by our proprietary SMART® (Switching Mechanism at 5' end of RNA Template) technology which enables sensitive and robust sequencing of single-cell or ultra-low-input RNA samples. "We remain focused on pushing the envelope of single-cell RNA-seq technology, and we are strongly committed to providing novel technologies for this rapidly evolving field," said Carol Lou, President of Takara Bio USA, Inc. "Our license on the gold-standard Smart-seq2 method enables us to further improve upon our original methods and allows researchers to push the limits of their own work." For more information about TBUSA products for next-generation sequencing, please visit: takarabio.com/products/next-generation-sequencing. About Takara Bio
View original content with multimedia:http://www.prnewswire.com/news-releases/takara-bio-strengthens-its-ip-position-on-single-cell-rna-seq-300682632.html SOURCE Takara Bio USA, Inc. |